Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1982 Mar;15(3):366–371. doi: 10.1128/jcm.15.3.366-371.1982

Rapid typing of herpes simplex virus based on immunological specificity of viral thymidine kinase and typing according to sensitivity to iododeoxyuridine.

J S Gronowitz, C F Källander, S Jeansson, J Wallin
PMCID: PMC272101  PMID: 6281306

Abstract

We describe two methods for typing of herpes simplex virus (HSV). One procedure is based on the finding that the multiplication of HSV type 1 strains in primary rabbit kidney cells is inhibited by 2 x 10(-5) M iododeoxyuridine, whereas growth of HSV type 2 strains is considerably less affected. Forty-nine different HSV isolates were typed according to this method. For all isolates except two the results were found to be in agreement with results obtained by another typing procedure, the counterimmunoelectroosmophoretic method (S. Jeansson, Appl. Microbiol. 24:96-100, 1972). One HSV type 1 isolate behaved as a type 2 strain and was found to be a deoxythymidine kinase-negative mutant strain. The other deviant strain exhibited an intermediate iododeoxyuridine sensitivity, thus being impossible to type with this method. Another, faster typing procedure which is based on the immunological difference between HSV type 1 and 2 deoxythymidine kinase is also presented. This assay, in combination with the conventional methods for isolation, enables the detection of deoxythymidine kinase-negative therapy-resistant HSV strains. Finally, we report the detection and typing of HSV deoxythymidine kinase present in vesicle fluids.

Full text

PDF
366

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cheng Y. C. A rational approach to the development of antiviral chemotherapy: alternative substrates of herpes simplex virus Type 1 (HSV-1) and Type 2 (HSV-2) thymidine kinase (TK). Ann N Y Acad Sci. 1977 Mar 4;284:594–598. doi: 10.1111/j.1749-6632.1977.tb21992.x. [DOI] [PubMed] [Google Scholar]
  2. Cheng Y. C., Tsou T. Y., Hackstadt T., Mallavia L. P. Induction of thymidine kinase and DNase in varicella-zoster virus-infected cells and kinetic properties of the virus-induced thymidine kinase. J Virol. 1979 Jul;31(1):172–177. doi: 10.1128/jvi.31.1.172-177.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coleman V. R., Tsu E., Jawetz E. "Treatment-resistance" to idoxuridine in herpetic keratitis. Proc Soc Exp Biol Med. 1968 Dec;129(3):761–765. doi: 10.3181/00379727-129-33419. [DOI] [PubMed] [Google Scholar]
  4. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  5. Dobersen M. J., Jerkofsky M., Greer S. Enzymatic basis for the selective inhibition of varicella-zoster virus by 5-halogenated analogues of deoxycytidine. J Virol. 1976 Nov;20(2):478–486. doi: 10.1128/jvi.20.2.478-486.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eriksson B., Larsson A., Helgstrand E., Johansson N. G., Oberg B. Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase. Biochim Biophys Acta. 1980 Mar 28;607(1):53–64. doi: 10.1016/0005-2787(80)90220-8. [DOI] [PubMed] [Google Scholar]
  7. Gronowitz J. S., Källander C. F. Occurrence of antibodies against herpes simplex virus thymidine kinase in human sera. J Med Virol. 1981;8(3):177–186. doi: 10.1002/jmv.1890080304. [DOI] [PubMed] [Google Scholar]
  8. Gronowitz J. S., Källander C. F. Optimized assay for thymidine kinase and its application to the detection of antibodies against herpes simplex virus type 1- and 2-induced thymidine kinase. Infect Immun. 1980 Aug;29(2):425–434. doi: 10.1128/iai.29.2.425-434.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jeansson S. Differentiation between herpes simplex virus type 1 and type 2 strains by immunoelectroosmophoresis. Appl Microbiol. 1972 Jul;24(1):96–100. doi: 10.1128/am.24.1.96-100.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kaufman H. E. Problems in virus chemotherapy. Prog Med Virol. 1965;7:116–159. [PubMed] [Google Scholar]
  11. Kit S. Viral-associated and induced enzymes. Pharmacol Ther B. 1979;4(3):501–585. doi: 10.1016/0163-7258(79)90004-4. [DOI] [PubMed] [Google Scholar]
  12. Person D. A., Sheridan P. J., Herrmann E. C. Sensitivity of Types 1 and 2 Herpes Simplex Virus to 5-Iodo-2'-Deoxyuridine and 9-beta-d-Arabinofuranosyladenine. Infect Immun. 1970 Dec;2(6):815–820. doi: 10.1128/iai.2.6.815-820.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Thouless M. E. Serological properties of thymidine kinase produced in cells infected with type 1 or type 2 herpes virus. J Gen Virol. 1972 Dec;17(3):307–315. doi: 10.1099/0022-1317-17-3-307. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES